The healthcare sector continues to draw attention from investors, particularly as advancements in pharmaceuticals and medical innovations unfold. As of March 8, 2026, MarketBeat’s stock screener has highlighted five medical stocks that are generating notable trading volumes and investor interest. These stocks, driven by innovations and developments in the healthcare field, offer a mix of established giants and emerging players poised for growth.

1. Eli Lilly (LLY)

Eli Lilly has solidified its position in the pharmaceutical industry, particularly with its portfolio of drugs targeting diabetes and obesity. Among these, Mounjaro, Trulicity, and Zepbound stand out as significant contributors to the company’s revenue and market interest. Mounjaro, for instance, has been gaining traction due to its effectiveness in managing type 2 diabetes, while Trulicity has established itself as a reliable treatment option for patients.

The strong performance of these products has not only bolstered Eli Lilly’s financials but has also drawn attention from investors looking for stability and growth in the ever-evolving healthcare market. As diabetes and obesity rates continue to rise globally, the demand for effective medications will likely sustain Eli Lilly’s momentum in the market.

2. UnitedHealth Group (UNH)

UnitedHealth Group remains a formidable player in the healthcare industry, combining health insurance with an expansive network of healthcare services. The company’s ability to integrate technology into its services has made it a leader in the health insurance sector. With a focus on improving patient outcomes through data-driven insights and personalized care, UnitedHealth has positioned itself strategically to benefit from the ongoing transformation within the healthcare landscape.

• Innovative Services: UnitedHealth has been expanding its telehealth services, making healthcare more accessible to patients, especially post-pandemic.
• Financial Performance: The company consistently reports strong earnings, making it a reliable investment choice.
• Growth Potential: UnitedHealth’s investments in technology and data analytics pave the way for future growth.

3. Johnson & Johnson (JNJ)

Johnson & Johnson, a staple in the healthcare industry, is widely recognized for its diverse product portfolio that spans pharmaceuticals, medical devices, and consumer health products. The company has been at the forefront of vaccine development, particularly during the COVID-19 pandemic, which has enhanced its reputation and market standing.

As Johnson & Johnson continues to innovate in various therapeutic areas, including oncology and immunology, it remains a compelling stock for investors. The company’s recent advancements in drug development and its commitment to research and development (R&D) underscore its potential for future growth.

4. Day One Biopharmaceuticals (DAWN)

For investors looking for higher-risk opportunities, Day One Biopharmaceuticals presents an intriguing option. The company is focused on developing targeted therapies for pediatric patients with cancer, specifically its lead candidate, tovorafenib, which is currently in Phase II clinical trials for treating relapsed or refractory low-grade glioma.

This focus on pediatric oncology sets Day One Biopharmaceuticals apart from many of its peers, as the need for effective treatments in this area is critical. While investing in clinical-stage companies carries inherent risks, the potential rewards can be substantial, especially if Day One can successfully advance its trials and bring new therapeutics to market.

5. Merck & Co. (MRK)

Merck & Co. is another key player to watch in the medical stock landscape. Known for its innovative approaches to pharmaceutical development, Merck has made headlines with its advancements in treatment options for various diseases, including cancer and infectious diseases. The company’s commitment to R&D has led to breakthroughs that have not only improved patient outcomes but have also positioned Merck as a leader in the pharmaceutical industry.

Investors are particularly interested in Merck’s pipeline of drugs, which includes promising candidates in various stages of development. With a robust portfolio and a history of successful product launches, Merck remains a trusted choice for those looking to invest in the healthcare sector.

Conclusion

The healthcare sector offers a dynamic landscape for investors, with a mix of stability from established companies and the potential for high returns from emerging players. As we look at the five medical stocks highlighted by MarketBeat—Eli Lilly, UnitedHealth, Johnson & Johnson, Day One Biopharmaceuticals, and Merck—each presents unique opportunities shaped by their respective strategies and market conditions.

Investors should consider their risk tolerance and investment strategies when evaluating these stocks, particularly with companies like Day One Biopharmaceuticals that are still in the clinical trial phase. However, the ongoing demand for innovative healthcare solutions ensures that these stocks will remain in the spotlight as the market continues to evolve.